Massive Transfusion Protocol — Trauma Hemorrhage

Key Points

• Activate MTP from clinical trajectory, not only after a retrospective unit count is reached.
• Prioritize hemorrhage control and blood-based resuscitation over large-volume crystalloid.
• Balanced component therapy or established whole-blood protocols are appropriate early strategies in exsanguinating trauma.
• Monitor ionized calcium and replace it during large-volume transfusion.
• Prevent hypothermia with active warming and warmed blood products.
• Use tranexamic acid early when indicated, generally within 3 hours of traumatic injury.
• Transition to laboratory or viscoelastic-directed component therapy as information becomes available.
• Terminate MTP promptly once hemorrhage is controlled to reduce transfusion-related complications.

Algorithm

1. Recognize active life-threatening hemorrhage and activate the trauma and massive transfusion pathways early.
2. Obtain large-bore or rapid-infusion access and send type and crossmatch, CBC, coagulation tests, fibrinogen, blood gas, lactate, and ionized calcium.
3. Begin emergency-release balanced blood components or whole blood according to institutional protocol.
4. Control external bleeding, stabilize the pelvis when indicated, and mobilize operative or interventional source control.
5. Give tranexamic acid when the patient meets the local early-trauma criteria and is within the effective time window.
6. Warm the patient and products and replace calcium while trending acid-base status and coagulation.
7. Use serial conventional or viscoelastic testing to target fibrinogen, platelet, plasma, and red-cell therapy.
8. Deactivate MTP when bleeding is controlled and continue surveillance for transfusion complications and organ injury.

Clinical Synopsis & Reasoning

Massive transfusion is a clinical pathway rather than a retrospective number of units. Activate it when ongoing hemorrhage and physiology suggest that ordinary blood ordering will be too slow, such as persistent hypotension, active major bleeding, penetrating torso injury, positive focused abdominal ultrasound with shock, pelvic hemorrhage, or rapid early transfusion requirement. Scoring systems can support activation, but a patient who is clearly bleeding to death should not wait for a score threshold.

Traumatic hemorrhagic shock is worsened by the lethal triad of hypothermia, acidosis, and coagulopathy, with hypocalcemia now recognized as another important component. Large crystalloid loads dilute clotting factors, worsen tissue edema, and contribute to hypothermia. Damage-control resuscitation therefore prioritizes blood products early, permissive hypotension in selected patients without traumatic brain injury, rapid hemorrhage control, and avoidance of unnecessary crystalloid before bleeding is controlled.

Initial laboratory studies include CBC, type and crossmatch, PT/INR, aPTT, fibrinogen, blood gas, lactate or base deficit, chemistry, and ionized calcium. Viscoelastic testing can identify fibrinogen deficiency, impaired clot strength, or hyperfibrinolysis and support targeted component therapy where available. Results should be trended, but active hemorrhage treatment must not pause while waiting for laboratory confirmation.

Treatment Strategy & Disposition

Many trauma systems begin with balanced plasma, platelets, and red cells approximating whole blood, commonly using ratios near 1:1:1 or 1:1:2 depending on protocol, or low-titer group O whole blood where established. The exact product strategy is system-specific, but the objective is early replacement of oxygen-carrying capacity and hemostatic components together. Emergency-release blood should be used when crossmatched products are not yet available and delay would be dangerous.

Tranexamic acid can be considered for patients with significant traumatic hemorrhage when given early, particularly within 3 hours of injury, according to local trauma protocol. It should not delay operative or interventional source control. Citrate in transfused blood binds calcium, so ionized calcium must be monitored and replaced during large-volume resuscitation. Warm blood products and the patient actively because even modest hypothermia impairs coagulation.

The MTP should transition from empiric balanced resuscitation to laboratory- or viscoelastic-guided therapy as soon as useful data are available. Persistent low fibrinogen may require cryoprecipitate or fibrinogen concentrate depending on local resources. Stop or de-escalate the protocol when hemorrhage is controlled to avoid unnecessary transfusion. Definitive hemostasis may require surgery, pelvic stabilization and angioembolization, resuscitative endovascular balloon occlusion in selected systems, or other source-specific interventions.

Epidemiology / Risk Factors

• Major hemorrhage is a leading preventable cause of early trauma death.
• Penetrating torso trauma, unstable pelvic fractures, major vascular injury, and severe solid-organ injury are common MTP triggers.
• Patients taking anticoagulants may require specific reversal in addition to blood-component therapy.
• Older patients and those with cardiopulmonary disease may tolerate anemia, acidosis, and volume shifts poorly.
• Standardized MTPs reduce delays and improve coordination during high-acuity hemorrhage.

Investigations

Early Orders Set

Pharmacology

Prognosis / Complications

• Survival depends heavily on speed of hemorrhage control and reversal of shock.
• Persistent acidosis, hypothermia, hypocalcemia, and coagulopathy are associated with worse outcomes.
• Transfusion itself carries risks, but in uncontrolled hemorrhage the immediate risk of undertreatment is far greater.
• Patients who survive massive transfusion may have prolonged ICU courses from organ injury, infection, and trauma burden.
• Early hemostatic resuscitation and coordinated source control improve the chance of survival compared with delayed component replacement.

Patient Education / Counseling

• When clinically possible after recovery, explain why emergency-release or uncrossmatched blood was required and review any transfusion reactions.
• Patients should be told about injuries and procedures that created future bleeding, thrombosis, or follow-up risks.
• Massive transfusion survivors should receive follow-up for anemia, organ injury, rehabilitation, and psychological effects of major trauma.
• Patients with newly identified antibodies or transfusion reactions should have that information clearly documented for future care.
• Anticoagulant or antiplatelet therapy should be restarted only through a risk-balanced plan appropriate to the original indication and bleeding control.
• Family communication during ongoing MTP should be realistic about both hemorrhage severity and the purpose of aggressive resuscitation.

Notes

The best MTP is integrated with source control. A blood-bank ratio alone cannot rescue ongoing uncontrolled vascular, pelvic, abdominal, thoracic, or junctional hemorrhage.

Once the initial emergency phase passes, transfusion should become increasingly targeted to measured deficits and ongoing clinical bleeding rather than continuing empiric packs automatically.

References

1. American College of Surgeons Trauma Quality Programs — Link
2. American College of Surgeons Advanced Trauma Life Support — Link